- 1. Overview 13
- 1.1 About this Report 13
- 1.2 Scope of the Report 14
- 1.3 Objectives 15
- 1.4 Methodology 15
- 1.5 Executive Summary 16
- 2. Overview of Diagnostic Testing Point of Care 20
- 2.1 Point of Care Testing Sites 20
- 2.2 Point of Care Market Structure 21
- 3. POCT and Rapid Testing Market Analysis: Size, Background Analysis, Growth, Share and Competitors 24
- 3.1 Global POCT Market 30
- 3.2 U.S. POCT Market 32
- 3.3 European POCT Market 34
- 3.3.1 German POCT Diagnostic Market 40
- 3.3.2 U.K. POCT Diagnostic Market 43
- 3.3.2.1 U.K. POCT Market Statistics 43
- 3.3.2.2 U.K. Competitive Analysis 45
- 3.3.2.3 U.K. Market Access 46
- 3.3.3 French POCT Diagnostic Market 46
- 3.3.4 Italian POCT Diagnostic Market 47
- 3.3.5 Spanish POCT Diagnostic Market 48
- 3.3.6 Scandinavian POCT Diagnostic Market 50
- 3.3.7 Swedish POCT Diagnostic Market 50
- 3.3.8 Finland POCT Diagnostic Market 51
- 3.3.9 Norway POCT Diagnostic Market 52
- 3.3.10 Swiss POCT Diagnostic Market 53
- 3.3.11 Dutch POCT Diagnostic Market 54
- 3.3.12 Belgian POCT Diagnostic Market 55
- 3.3.13 Portugal POCT Diagnostic Market 56
- 3.3.14 Austria POCT Diagnostic Market 57
- 3.3.15 Greek POCT Diagnostic Market 58
- 3.3.16 Poland POCT Diagnostic Market 59
- 3.3.17 Czech Republic POCT Diagnostic Market 60
- 3.3.18 Turkish POCT Diagnostic Market 61
- 3.4 Asian POCT Markets 62
- 3.4.1 Japanese POCT Diagnostic Market 62
- 3.4.2 Indian POCT Diagnostic Market 63
- 3.4.3 Chinese POCT Diagnostic Market 69
- 3.5 Rest of the World POCT Market 78
- 3.5.1 Canada POCT Diagnostic Market 78
- 3.5.2 Brazil POCT Diagnostic Market 79
- 3.5.3 Australia POCT Diagnostic Market 79
- 3.6 Overview of Asian Healthcare Market 80
- 3.6.1 Singapore 81
- 3.6.2 Malaysia 82
- 3.6.3 Thailand 82
- 3.6.4 Indonesia 83
- 3.6.5 Philippines 83
- 3.6.6 South Korea 83
- 3.6.7 Taiwan 84
- 4. POCT Individual Markets 85
- 4.1 Glucose Testing 85
- 4.2 POCT Individual Market Sectors, Size, Growth Rates and Competitors 87
- 4.2.1 World Market 87
- 4.2.2 U.S. Market 87
- 4.2.3 European Market 89
- 4.2.4 Alternate Glucose Monitoring Products 90
- 4.2.5 HbA1c POCT 90
- 4.3 Blood Gas and Electrolytes 91
- 4.3.1 Whole Blood Lactate 94
- 4.4 Rapid Coagulation Tests 94
- 4.4.1 World POCT Coagulation Market 97
- 4.4.2 U.S. Coagulation Market 97
- 4.4.3 European Coagulation Market 100
- 4.4.4 Trends in POCT Coagulation Testing 100
- 4.5 Rapid Cardiac Markers 101
- 4.5.1 U.S. Market 101
- 4.5.2 European Market 103
- 4.6 Drugs of Abuse Screening Testing 104
- 4.6.1 Acetaminophen 111
- 4.6.2 Tricyclic Antidepressants (TCAs) 111
- 4.6.3 Other Toxic Drugs 112
- 4.6.4 Drug Testing Selectivity 112
- 4.6.5 Methaqualone and Phencyclidine (PCP) 112
- 4.6.6 Tetrahydrocannabinol 112
- 4.6.7 Drug Panels by Toxidromes 112
- 4.6.8 Alcohol Testing 113
- 4.7 Urine Strips 113
- 4.8 Pregnancy Tests 116
- 4.9 Fecal Occult Blood 118
- 4.10 Hemoglobin Testing 119
- 4.11 Miscellaneous Rapid Tests 119
- 4.11.1 Estriol 119
- 4.11.2 Fetal Fibronectin (fFN) 120
- 4.11.3 H. pylori 120
- 4.11.4 Vaginal pH and Vaginitis 120
- 4.11.5 Bladder Cancer 121
- 4.11.6 Fetal Status 122
- 4.11.7 Heparin-Induced Thrombocytopenia 123
- 4.12 Human Immunodeficiency Virus (HIV) 123
- 4.13 Cholesterol 129
- 4.14 Infectious Disease 130
- 4.14.1 C. difficile 130
- 4.14.2 Giardia 131
- 4.14.3 Salmonella and Campylobacter 132
- 4.14.4 Malaria Testing 132
- 4.14.5 Influenza Testing 134
- 4.14.6 Strep Testing 135
- 4.14.7 Chlamydia 137
- 4.14.8 Mononucleosis 138
- 4.14.9 Rubella 138
- 4.14.10 Methicillin-Resistant Staphylococcus Aureus (MRSA) 138
- 4.14.11 Hepatitis 145
- 4.14.12 Gonorrhea 147
- 4.14.13 Tuberculosis (TB) 148
- 4.14.14 Herpes Simplex Virus Type-2 150
- 4.15 Infant Jaundice 150
- 4.16 Anthrax 150
- 4.17 Rupture of Fetal Membranes (ROM) 152
- 4.18 Food Pathogens 152
- 4.19 Typhoid 152
- 5. POCT: Reagents and Equipment 153
- 5.1 Blood Glucose Monitoring 153
- 5.1.1 LifeScan 154
- 5.1.2 Roche Accu-Chek 157
- 5.1.3 Siemens Healthcare Diagnostics 157
- 5.1.4 Cholestech (Acquired by Inverness Medical Innovations) 159
- 5.1.5 Abbott Diabetes Care 159
- 5.1.6 International Technidyne Corporation 160
- 5.1.7 HemoCue 161
- 5.1.8 Stanbio/GDS Technology 161
- 5.1.9 Disetronic Medical Systems 162
- 5.1.10 Medtronic MiniMed 162
- 5.1.11 Abaxis 163
- 5.2 Blood Gas and Electrolytes 166
- 5.2.1 Roche Corporation 166
- 5.2.2 TechnoMedica 167
- 5.2.3 Siemens Healthcare Diagnostics 167
- 5.2.4 Instrumentation Laboratory 167
- 5.2.5 Nova Biomedical 167
- 5.2.6 Radiometer 168
- 5.2.7 Abbott Laboratories 168
- 5.2.8 Span Diagnostics 168
- 5.2.9 Avox Systems 168
- 5.2.10 ITC 170
- 5.2.11 OPTImedical 170
- 5.3 Rapid Coagulation Tests 170
- 5.3.1 POC Coagulation Instrument Description 175
- 5.3.1.1 Roche Diagnostics Corp. 175
- 5.3.1.2 Abbott Laboratories 177
- 5.3.1.3 International Technidyne Corp. 177
- 5.3.1.4 Medtronic 178
- 5.3.1.5 HemoSense (Inverness) 179
- 5.3.1.6 Helena Laboratories Point of Care 179
- 5.3.1.7 Sienco, Inc. 180
- 5.3.1.8 Accumetrics 181
- 5.3.2 Connectivity Issues 181
- 5.3.3 Cost Benefits 181
- 5.3.4 Quality Control Issues 182
- 5.3.5 Certification for POC Coagulation Devices 182
- 5.4 Rapid Cardiac Markers 183
- 5.4.1 Nanogen 183
- 5.4.2 Biosite Diagnostics (Inverness) 183
- 5.4.3 Roche Diagnostics 184
- 5.4.4 Ani Biotech 185
- 5.4.5 Response Biomedical Corporation 185
- 5.4.6 Siemens Healthcare Diagnostics 186
- 5.4.7 Lab21 Limited 187
- 5.4.8 Abbott Laboratories 187
- 5.4.9 LifeSign (Princeton BioMediTech Corp) 187
- 5.4.10 Mitsubishi Kagaku Iatron 187
- 5.5 Rapid Drugs of Abuse 187
- 5.5.1 Biosite Diagnostics (now a brand of Inverness Medical Innovations) 189
- 5.5.2 Abbott Diagnostics 190
- 5.5.3 Roche Diagnostics 190
- 5.5.4 BioScan Screening Systems, Inc. 191
- 5.5.5 American Bio Medica Corp. 192
- 5.5.6 Phamatech, Inc. 195
- 5.5.7 Worldwide Medical 196
- 5.5.8 OraSure 196
- 5.5.9 LifePoint 196
- 5.5.10 Avitar, Inc. 197
- 5.5.11 Cozart Biosciences 197
- 5.5.12 Pathtech 198
- 5.5.13 Alfa Scientific Designs, Inc. 198
- 5.5.14 TCPI, Inc. 198
- 5.5.15 Roche 199
- 5.5.16 Siemens Corporation 199
- 5.5.17 Diagnostic Chemical, Ltd. 200
- 5.5.18 Quidel 200
- 5.5.19 HemoCue (Quest) 200
- 5.6 Rapid Pregnancy and Fertility Tests 200
- 5.7 Fecal Occult Blood 202
- 5.7.1 Helena Laboratories 203
- 5.7.2 Biomerica 203
- 5.7.3 Beckman Coulter 203
- 5.7.4 Worldwide Medical 203
- 5.7.5 Aerscher Diagnostics 203
- 5.7.6 Enterix 204
- 5.7.7 Medix Biochemica 204
- 5.8 Hemoglobin Testing 204
- 5.8.1 Wampole Laboratories 204
- 5.8.2 HemoCue, Inc. 204
- 5.8.3 Stanbio/GDS Technology 205
- 5.9 Miscellaneous Rapid Tests 205
- 5.9.1 Triage C. difficile Panel 205
- 5.9.2 Ketoacids 205
- 5.9.3 Acetaminophen 205
- 5.9.4 Estriol 206
- 5.9.5 H. pylori 206
- 5.9.6 Vaginal Fluid pH and Vaginitis 208
- 5.9.7 Prostate Specific Antigen (PSA) 209
- 5.9.8 Bladder Cancer 209
- 5.9.9 Other Rapid Cancer Tests 212
- 5.9.10 Fetal Status (PROM) 213
- 5.9.11 Osteoporosis 213
- 5.9.12 Hemodynamic Monitoring 213
- 5.9.13 Heparin-Induced Thrombocytopenia 214
- 5.10 HIV 214
- 5.10.1 Whole Blood, Serum or Plasma-Based HIV Tests 216
- 5.10.1.1 Bio-Rad Laboratories 216
- 5.10.1.2 Orgenics (wholly-owned by Inverness Medical Innovations) 216
- 5.10.1.3 StatSure Diagnostic Systems 217
- 5.10.1.4 Trinity Biotech 217
- 5.10.1.5 Savyon Diagnostics 217
- 5.10.1.6 MedPharm 217
- 5.10.1.7 American Bio Medica Corp. 217
- 5.10.1.8 Chembio Diagnostics 218
- 5.10.1.9 OraSure 218
- 5.10.1.10 Inverness 219
- 5.10.2 Saliva-Based HIV Tests 219
- 5.10.2.1 OraSure Collection Device 220
- 5.10.2.2 SureStat 221
- 5.10.3 Urine-Based HIV Tests 221
- 5.10.3.1 MedMira Laboratories, Inc. 221
- 5.10.3.2 Medical Services International, Inc. 222
- 5.10.3.3 Maxim Biomedical 222
- 5.10.3.4 Wampole Laboratories 222
- 5.11 Cholesterol 222
- 5.11.1 Cholestech (Now a Brand of Inverness Medical Innovations) 223
- 5.11.2 Actimed Laboratories 224
- 5.11.3 StatSite Meter 224
- 5.11.4 Polymer Technology Systems 225
- 5.11.5 PreMD Inc. (f/k/a International Medical Innovations, Inc. (IMI)) 225
- 5.11.6 Abaxis, Inc. 225
- 5.12 Infectious Disease 225
- 5.12.1 C. difficile 225
- 5.12.2 Giardia 226
- 5.12.3 Dengue Fever 227
- 5.12.4 Malaria Testing 227
- 5.12.5 Rapid Influenza Testing 229
- 5.12.6 Streptococcus Testing 229
- 5.12.7 Chlamydia 231
- 5.12.8 Mononucleosis 231
- 5.12.9 Rubella 233
- 5.12.10 Staphylococcus Aureus and MRSA 233
- 5.12.11 Hepatitis 234
- 5.12.12 E. Coli O157 236
- 5.12.13 Gonorrhea Testing 236
- 5.12.14 Smallpox 236
- 5.12.15 SARS 236
- 5.12.16 Rabies 236
- 5.12.17 Tuberculosis 237
- 5.12.18 Avian Flu 237
- 5.12.19 West Nile Virus 237
- 5.12.20 Herpes Simplex Virus Type-2 237
- 5.13 Infant Jaundice 238
- 5.14 Anthrax 238
- 5.15 Homeland Defense (Plague and Tularemia) 239
- 5.16 BSE (Mad Cow Disease) 239
- 5.17 Tuberculosis 240
- 5.18 Typhoid 240
- 5.19 Avian Flu 240
- 5.20 Food Pathogens (Salmonella, Listeria, Campylobacter) 241
- 5.21 Ruptured Fetal Membranes (ROM) 242
- 6. POCT: Growth Regulators 243
- 6.1 Moderators of Growth 243
- 6.2 Personnel Acceptance 243
- 6.3 Key People for POCT 244
- 6.4 Information Management Issues 244
- 6.4.1 Elements of Information Management for POCT: Information Processing Capabilities 245
- 6.4.2 Data Mining 246
- 6.4.3 Middleware 246
- 6.4.4 Web Portals 247
- 6.4.5 POCT-1A Standard 247
- 6.5 Key Elements for POCT 248
- 6.6 POCT and Reimbursement 248
- 6.7 Effectiveness of Clinical Outcomes 250
- 6.8 Rapid Near-Patient Testing in Hospitals 250
- 6.9 Satellite Facilities 251
- 6.10 Regionalization of Laboratory Care 252
- 6.11 Requirements for POCT 253
- 6.12 Locations of Point of Care for Patient Care 254
- 6.13 Benefits of POCT 254
- 6.14 Cost Elements of POCT 254
- 6.15 Necessary Functions in POCT 255
- 6.16 TAT for POCT 255
- 6.17 Clinical Laboratory Improvement Amendments (CLIA) 255
- 6.18 Sexually-Transmitted Diseases in Underdeveloped Countries 257
- 7. Business Trends in the Point of Care Sector 258
- 7.1 Sector Consolidation 258
- 7.2 Diagnostic Testing Growth Trends 258
- 7.3 Acquisition, License Agreements, Internal Development and Partnerships 259
- 7.4 Product Testing Depth in POCT 263
- 7.5 Government Regulation 263
- 7.5.1 U.S. Regulation 263
- 7.5.1.1 Importing Medical Devices into the U.S. 264
- 7.5.1.2 Exporting Medical Devices from the U.S. 265
- 7.5.2 U.K. Regulation 265
- 7.5.3 E.U. Regulation 267
- 7.5.3.1 French Regulation 268
- 7.5.4 Japanese Regulation 269
- 7.5.5 Korean Regulation 269
- 7.6 Increased Market Penetration 269
- 7.7 Costs of Doing Business in Europe 270
- 7.8 Drivers of European Diagnostics Testing 271
- 7.9 European Reimbursement Practices 271
- 7.10 Cost Containment in Europe 271
- 8. Technology Platform Innovations in POCT 272
- 8.1 Sensor Systems for Diagnostic Applications 272
- 8.2 Glucose Measurements 275
- 8.3 Glucose Test Methods 277
- 8.4 Cholesterol Testing 278
- 8.5 The New Paradigm 279
- 8.6 Consolidated Workstations and Modularity 279
- 8.7 Automation and Robotics in the Clinical Laboratory 279
- 8.8 Laboratory Information Systems (LIS) 280
- 8.8.1 NOVIUS Lab 280
- 8.9 Biosensor Technology 280
- 8.10 Nanogen Third Generation POC Analyzer 282
- 8.11 Quidel MChip 283
- 9. Data Management and Connectivity 284
- 9.1 Wireless LANs 284
- 9.2 Connectivity Platforms 286
- 9.2.1 DataLink Data Management System 287
- 9.2.2 RALS-Plus 288
- 9.2.2.1 International Technidyne Corporation HEMOCHRON Signature Elite 289
- 9.2.2.2 Siemens Diagnostics Rapidpoint® Coag 290
- 9.2.2.3 Radiometer 290
- 9.2.2.4 HemoCue's DM Hemoglobin 290
- 9.2.2.5 Roche Diagnostics 290
- 9.2.3 BD.id 291
- 9.2.4 Medical Implant Communications Service (MICS) 291
- 9.3 Advantages of POCT Connectivity 291
- 9.3.1 Cost Benefit of POCT and IT Connectivity 291
- 9.3.2 Hospital Network Issues 292
- 10. Corporate Profiles 293
- 10.1 Abaxis, Inc. 293
- 10.2 Abbott Diagnostics 297
- 10.3 Accumetrics, Inc. 300
- 10.4 Accurex Biomedical, Pvt., Ltd. 301
- 10.5 Akers Biosciences 301
- 10.6 Alfa Scientific Design, Inc. 301
- 10.7 Ambri, Ltd. 301
- 10.8 American Bio Medica Corp. 302
- 10.9 Ani Biotech 303
- 10.10 Apogent Technologies 303
- 10.11 Ark Therapeutics 303
- 10.12 ARKRAY 304
- 10.13 Atlas Genetics 304
- 10.14 Atonomics 304
- 10.15 Avitar, Inc. 304
- 10.16 Avox Systems 305
- 10.17 Axis-Shield 305
- 10.18 Beckman Coulter 306
- 10.19 Binax Corporation 310
- 10.20 Biomerica 310
- 10.21 BioMérieux Vitek, Inc. 311
- 10.22 BioScan Screening Systems, Inc. 311
- 10.23 Biosite Diagnostics 311
- 10.24 BioStar 311
- 10.25 British Biocell Holdings 311
- 10.26 Caliper Life Sciences 312
- 10.27 Calypte Biomedical 313
- 10.28 Chembio Diagnostics 313
- 10.29 Cholestech 314
- 10.30 Chongqing Sungene Pharmaceutical Co., Ltd. 314
- 10.31 CompuCyte Corporation 315
- 10.32 Cortech Diagnostics Ltd. (Now Called Kent International Holdings) 315
- 10.33 Cozart Biosciences 315
- 10.34 Cygnus Therapeutic Systems 315
- 10.35 Cytogen 316
- 10.36 DexCom 316
- 10.37 Daiichi Sankyo Group 317
- 10.38 Denka Seiken Co., Ltd. 317
- 10.39 Diagnostic Chemicals, Ltd. 317
- 10.40 Enterix, Inc. 317
- 10.41 Focus Diagnostics, Inc. 317
- 10.42 GDS Technology 317
- 10.43 GenBio 318
- 10.44 Genzyme Diagnostics 318
- 10.45 Grant Life Sciences 320
- 10.46 Gryphus Diagnostics 320
- 10.47 Helena Laboratories 321
- 10.48 Hema Diagnostic Systems 321
- 10.49 Hemocue, Inc. 322
- 10.50 Home Access Health Corp. 322
- 10.51 Immunoscience, Inc. 322
- 10.52 Instrumentation Laboratory 322
- 10.53 International Medical Innovations 323
- 10.54 Inverness Medical Innovations 323
- 10.55 Johnson & Johnson 328
- 10.56 Kyowa Medex Co., Ltd. 330
- 10.57 LifeAssays 330
- 10.58 LifePoint, Inc. 330
- 10.59 LifeScan Corporation 330
- 10.60 Lifestream Technologies 331
- 10.61 LXN Corp. (Inverness Medical Technologies) 331
- 10.62 Matritech 331
- 10.63 Medical Services International, Inc. 331
- 10.64 MediSense 332
- 10.65 Medisys 332
- 10.66 Medix Biochemica 332
- 10.67 MedMira Laboratories 332
- 10.68 Meretek Corporation 334
- 10.69 Meridian Bioscience 334
- 10.70 MiniMed 336
- 10.71 Mitsubishi Chemical U.S.A, Inc. 336
- 10.72 Mitsubishi Kagaku Iatron 337
- 10.73 Nanogen 337
- 10.74 New Horizons Diagnostics 338
- 10.75 Nova Biomedical 338
- 10.76 OraSure 340
- 10.77 Orgenics 344
- 10.78 Orion Diagnostica 344
- 10.79 PanBio, Ltd. 344
- 10.80 Phamatech, Inc. 344
- 10.81 PharmaNetics, Inc. 345
- 10.82 Polymedco 345
- 10.83 Polymer Technology Systems 346
- 10.84 Princeton BioMeditech Corporation 346
- 10.85 Quest Diagnostics 346
- 10.86 Quidel 347
- 10.87 Radiometer 351
- 10.88 Response Biomedical Corp. 353
- 10.89 Roche Diagnostics 354
- 10.90 Royal Philips Electronics 355
- 10.91 Savyon Diagnostics 356
- 10.92 Selfcare, Inc. 357
- 10.93 Shanghai Siic Kehua Biotech Co., Ltd. (Kehua Biotech) 357
- 10.94 Shionogi & Co., Ltd. 357
- 10.95 Siemens Corporation 357
- 10.96 SpectRx, Inc. 358
- 10.97 Spectral Diagnostics 359
- 10.98 StatSure Diagnostic Systems 359
- 10.99 Strategic Diagnostics 360
- 10.100 Sun Biomedical Laboratories 360
- 10.101 Thoratec/International Technidyne Corp. 360
- 10.102 Transmedica 362
- 10.103 Trinity Biotech 362
- 10.104 Vasamed, Inc. 364
- 10.105 Venkateshwara Hatcheries Pvt., Ltd. 365
- 11. POCT Sector Trends and Forecasts 366
- 11.1 Home Care Analysis as Part of Near-Patient Testing 366
- 11.2 Non-Traditional Collection for POCT 366
- 11.3 New Systems for Critical Care and Near-Patient Testing 366
- 11.4 Utility of Near-Patient Testing in Critical Care Settings 366
- 11.5 Physician's Office Market 367
- 11.6 Information Management Advances 367
- 11.7 Test-Ordering Patterns and Demand for POCT 368
- 11.8 Demand for Emergency Department Services 368
- 11.9 Move Away From Central Laboratory 369
- 11.10 Healthcare Cost Controls 370
- 11.11 M&A in POCT 370
- 11.12 Competition for Services 370
- 11.13 Drivers of POCT 371
- 11.14 Confluence of New Technology 371
- 11.15 Difficulties of Design for POC Products 371
- 11.16 European Hospital Structure 372
- 11.17 The Biggest New Opportunities in Point of Care Testing 372
- 12. Corporate Directory 373
- LIST OF TABLES
- Table 2.1: Percentage of Point of Care Testing Performed in Selected Hospitals 21
- Table 2.2: Point of Care Testing Procedural Advantages for Hospital Testing 23
- Table 2.3: Point of Care Testing Trends 23
- Table 2.4: Professional Point of Care Testing Compared to Home Testing 23
- Table 2.5: Drivers for Integrating Point of Care Testing into Hospital Routines 23
- Table 3.1: Actual Reported Number of ER Visits in U.S. Hospitals, 1997-2008 24
- Table 3.2: Number of Point of Care Tests in U.S., 2000-2012 25
- Table 3.3: Global Clinical Laboratory Market Sales, 1998-2010 27
- Table 3.4: Overall In Vitro Diagnostic Testing Market Worldwide, 2007 28
- Table 3.5: Worldwide Distribution of IVD Testing, 2008 28
- Table 3.6: Top Twelve Country IVD Testing Markets, 2007 29
- Table 3.7: Thirteen Largest Diagnostic Companies Worldwide, 2007
|
|
|
|